The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChina Pacific Regulatory News (CPIC)

Share Price Information for China Pacific (CPIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.30
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 17.30
CPIC Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of 2021 AGM

28 Apr 2022 16:01

RNS Number : 7588J
China Pacific Insurance Grp Co. Ltd
28 April 2022
 

28 April 2022

CHINA PACIFIC INSURANCE (GROUP) CO., LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability)

Notice of the 2021 Annual General Meeting

 

NOTICE IS HEREBY GIVEN that the annual general meeting ("AGM" or "Annual General Meeting") of China Pacific Insurance (Group) Co., Ltd. (the "Company" or "CPIC") will be held at Hyatt Regency Chongming, Lane 799, Lanhai Road, Chenjia Town, Chongming District, Shanghai, on Wednesday, 8 June 2022 at 1:30 p.m., for the purpose of considering, and if thought fit, passing the following resolutions.

 

AS ORDINARY RESOLUTIONS:

 

1. To consider and approve the report of the Board of Directors of the Company for the year 2021

 

2. To consider and approve the report of the Board of Supervisors of the Company for the year 2021

 

3. To consider and approve the annual report of the Company for the year 2021

 

4. To consider and approve the financial statements and report of the Company for the year 2021

 

5. To consider and approve the profit distribution plan of the Company for the year 2021

 

6. To consider and approve the proposal on the appointment of auditors of the Company for the year 2022

 

7. To consider and approve the proposal on adoption of PRC ASBEs in preparation of financialstatements for H-share market

 

8. To consider and approve donations of the Company for the year 2022

 

AS SPECIAL RESOLUTIONS:

 

9. As special business, to authorise the Board of Directors of the Company to determine if the Company shall allot, issue and deal with, A Shares and H Shares, separately or concurrently, according to market conditions and the needs of the Company, provided that the respective number of shares shall not exceed 20% of each of the A Shares or H Shares of the Company in issue on the date of the passing of this special resolution. However, notwithstanding the granting of the general mandate to the Board of Directors, any issue of new A Shares would require another shareholders' approval at a Shareholders' meeting in accordance with the relevant PRC laws and regulations.

 

(1) Subject to paragraphs (3) and (4) below and pursuant to the Company Law of the People's Republic of China (the "Company Law") and the relevant regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed, the Board of Directors shall be granted a general and unconditional mandate to exercise all the powers of the Company to allot, issue and deal with new shares during the Relevant Period (as hereinafter defined) and to determine the terms and conditions for the allotment and issue of new shares which include, without limitation, the following terms:

 

(a) the class and number of new shares to be issued;

 

(b) the method of determining the issue price and/or the issue price (including the price range of new Shares);

 

(c) the starting and closing dates for the issue;

 

(d) class and number of the new shares to be issued to existing shareholders; and

 

(e) the making or granting of offers, agreements and options which might require the exercise of such powers.

 

(2) The approval in paragraph (1) shall authorise the Board of Directors during the Relevant Period to make or grant offers, agreements and options which would or might require the exercise of such powers after the end of the Relevant Period.

 

(3) The aggregate nominal amount of the new A Shares and new H Shares allotted, issued and dealt with conditionally or unconditionally (whether pursuant to an option or otherwise) by the Board of Directors pursuant to the approval in paragraph (1), other than the shares issued pursuant to a Rights Issue (as hereinafter defined) or the rights to purchase the shares of the Company under any option scheme or similar arrangement, shall not exceed 20% of each of the A Shares and H Shares of the Company in issue as at the date of passing this resolution.

 

(4) In exercising the powers granted in paragraph (1), the Board of Directors must (a) comply with the Company Law and the relevant regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed; and (b) obtain approval from China Securities Regulatory Commission and other relevant PRC government departments.

 

(5) For the purpose of this resolution:

 

"Relevant Period" means the period from the date of passing this resolution until the earliest of:

 

(a) the conclusion of the next annual general meeting of the Company;

 

(b) the expiration of the 12-month period following the passing of this resolution; and

 

(c) the revocation or variation of the mandate granted under this resolution by a special resolution of the Company's shareholders in a general meeting.

 

"Rights Issue" means the allotment or issue of shares in the Company or other securities which would or might require shares to be allotted and issued pursuant to an offer made to all the shareholders of the Company (excluding for such purpose any shareholder who is resident in a place where such offer is not permitted under the law of that place) and, where appropriate, the holders of other equity securities of the Company entitled to such offer, pro rata (apart from fractional entitlements) to their existing holdings of shares or such other equity securities.

 

(6) The Board of Directors, subject to the approval of the relevant authorities of the PRC and in accordance with the Company Law, shall be authorised to increase the registered capital of the Company to the required amount upon the exercise of the powers pursuant to paragraph (1) above.

 

(7) The Board of Directors shall be authorised to sign the necessary documents, complete the necessary formalities and take other necessary steps to complete the allotment, issue and listing of new shares, provided that the same do not violate the relevant laws, administrative regulations, and regulatory stipulations (as amended from time to time) of the places where the shares of the Company are listed, and the Articles of Association.

 

(8) Subject to the approval of the relevant PRC authorities, the Board of Directors shall be authorised to make amendments to the Articles of Association as appropriate and necessary after the completion of the allotment and issue of new shares according to the method of the allotment and issue of new shares by the Company, the type and number of new shares to be allotted and issued by the Company, and the actual shareholding structure of the Company at the time of completion of the allotment and issue of new shares, in order to reflect the changes in the share capital structure and the registered capital of the Company pursuant to the exercise of this mandate.

 

To authorise the Board to increase the registered capital of the Company to reflect the number of shares authorized to be issued by the Company pursuant to paragraph 1 of the Special Resolution, subject to the resolution to issue shares under paragraph 1 of the Special Resolution, make such amendments to the Articles of Association as he deems appropriate and necessary to reflect the increase in the registered capital of the Company, and to take any other actions and carry out any formalities required to realize the issuance of shares and the increase of the registered capital of the Company pursuant to paragraph 1 of the Special Resolution.

 

10. To consider and approve the proposed amendments to the Articles of Association of the Company in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Articles of Association as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Articles of Association.

 

11. To consider and approve the proposed amendments to the Procedural Rules for Shareholders' General Meetings in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Procedural Rules for Shareholders' General Meetings as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for Shareholders' General Meetings.

 

12. To consider and approve the proposed amendments to the Procedural Rules for the Board of Directors in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman or his authorized person to make such revisions to the Procedural Rules for the Board of Directors as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for the Board of Directors.

 

13. To consider and approve the proposed amendments to the Procedural Rules for the Board of Supervisors in the manner as set out in the section headed "8. Proposed Amendments to The Articles of Association, The Procedural Rules for Shareholders' General Meetings, The Procedural Rules for the Board of Directors and The Procedural Rules for the Board of Supervisors" in the circular of the Company dated 29 April 2022, to grant an authorization to the chairman of the Board of Supervisors or his authorized person to make such revisions to the Procedural Rules for the Board of Supervisors as he deems necessary and appropriate in accordance with the requirements of regulatory authorities during the Company's approval process for the Procedural Rules for the Board of Supervisors.

 

REPORTS TO BE REVIEWED

 

14. In relation to the report on performance of Directors and appraisal results of the Company for the year 2021

 

15. In relation to the report on performance of Supervisors and appraisal results of the Company for the year 2021

 

16. In relation to the report on performance of independent Directors of the Company for the year 2021

 

17. The report on the status of related party transactions and the implementation of management system for related party transactions of the Company for the year 2021.

 

 

For details on above resolutions and reports, please see the Appendices at http://www.rns-pdf.londonstockexchange.com/rns/7588J_1-2022-4-28.pdf

 

 

By Order of the Board of Directors

China Pacific Insurance (Group) Co., Ltd.

KONG Qingwei

Chairman

 

 

About CPIC

CPIC is a joint stock company established under the laws of the People's Republic of China with limited liability.

CPIC's registered office is located at 1 South Zhongshan Road, Huangpu District, Shanghai, the People's Republic of China.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAPPUMACUPPGCR
Date   Source Headline
28th Jun 202311:26 amRNSDirector/PDMR Shareholding
14th Jun 202310:04 amRNSAnnouncement relating to Premium Income
13th Jun 202310:57 amRNSDirector/PDMR Shareholding
13th Jun 202310:54 amRNSDirector/PDMR Shareholding
13th Jun 202310:53 amRNSDirector/PDMR Shareholding
13th Jun 202310:53 amRNSDirector/PDMR Shareholding
26th May 202311:54 amRNSAnnouncement on Poll Results for the 2022 AGM
12th May 20239:53 amRNSAnnouncement relating to Premium Income
27th Apr 20231:10 pmRNS2023 First Quarter Report
27th Apr 202312:58 pmRNSPublication of Summaries of Solvency Reports
21st Apr 20232:23 pmRNS2022 Sustainability Report
21st Apr 20232:03 pmRNSNotice of the 2022 AGM
17th Apr 202311:59 amRNSAnnouncement relating to Premium Income
27th Mar 20237:00 amRNSPublication of Summaries of Solvency Reports
27th Mar 20237:00 amRNSPublication of 2022 Annual Results Presentation
27th Mar 20237:00 amRNSAnnual Financial Report
24th Mar 20232:15 pmRNSResignation of Director
16th Mar 202311:11 amRNSConvening of 2022 Annual Results Presentation
15th Mar 20239:00 amRNSAnnouncement relating to Premium Income
17th Feb 20239:35 amRNSAnnouncement relating to Premium Income
17th Jan 20239:30 amRNSAnnouncement relating to Premium Income
6th Jan 20239:52 amRNSRemuneration of Part of PDMR
14th Dec 20228:56 amRNSAnnouncement relating to Premium Income
23rd Nov 20224:56 pmRNSFollow-up Anncmnt on Q3 Investor Events
16th Nov 202210:28 amRNS2022 Q3 RESULTS PRESENTATION AND 2022 INVESTOR DAY
16th Nov 202210:11 amRNSAnnouncement relating to Premium Income
28th Oct 202212:18 pmRNSSummaries of Quarterly Solvency Reports
28th Oct 202212:07 pmRNS2022 Third Quarter Report
18th Oct 20229:17 amRNSAnnouncement relating to Premium Income
15th Sep 202210:01 amRNSAnnouncement relating to Premium Income
7th Sep 20229:48 amRNSResignation of Director
30th Aug 20227:00 amRNS2022 Interim Results Presentation Materials
30th Aug 20227:00 amRNSCPIC 2022 Interim Report
30th Aug 20227:00 amRNSPublication of Summaries of Solvency Reports
18th Aug 202212:22 pmRNSAnnouncement re 2022 Interim Results Presentation
12th Aug 202210:05 amRNSAnnouncement relating to Premium Income
11th Aug 20223:52 pmRNSApproval of Articles of Association by CBIRC
27th Jul 20224:47 pmRNSPDMR Shareholding
15th Jul 202211:11 amRNSAnnouncement relating to Premium Income
10th Jun 20221:50 pmRNSAnnouncement relating to Premium Income
8th Jun 20224:01 pmRNSPDMR Shareholding
8th Jun 20223:58 pmRNSPDMR Shareholding
8th Jun 20223:55 pmRNSDirector Shareholding
8th Jun 20223:52 pmRNSPDMR Shareholding
8th Jun 20223:46 pmRNSPDMR Shareholding
8th Jun 20223:42 pmRNS2021 AGM Poll Results
6th Jun 20227:00 amRNSPDMR Shareholding
6th Jun 20227:00 amRNSDirector Shareholding
30th May 20224:37 pmRNSDirector Shareholding
24th May 20225:43 pmRNSDirector Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.